Company intelligence / Profile preview

Stemmatters

Guimarães, Portugal

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Stemmatters operates as a hybrid CDMO and biotech innovator specializing in cell/tissue products and advanced therapy medicinal products, particularly for regenerative medicine. It focuses on process development, GMP manufacturing, and biomaterial-enabled combination therapeutics for clients and partners, alongside developing its internal preclinical pipeline.

Therapeutic areas: Other
Modalities: Cell therapyBiologicBlood-derived biologicalsExosome-based therapyMedical deviceCombination productBiomaterialAdvanced therapy medicinal product
Industry: Biotech

Drug pipeline

1 asset

CAR T-REX

Preclinical

Partnerships

PluristyxMicrofluidXCAR T-REX International ConsortiumPAT4CGT International Consortium

Beyond the preview

Go deeper on Stemmatters.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stemmatters.

Explore the full profile